The human pregnane X receptor (PXR), a master regulator of drug metabolism, has important roles in intestinal homeostasis and abrogating inflammation. Existing PXR ligands have substantial off-target toxicity. Based on prior work that established microbial (indole) metabolites as PXR ligands, we proposed microbial metabolite mimicry as a novel strategy for drug discovery that allows to exploit previously unexplored parts of chemical space. Here we report functionalized indole-derivatives as firstin-class PXR selective non-cytotoxic agonists, as a proof-of-concept for microbial metabolite mimicry.
Introduction
Microbial metabolite mimicry has been proposed as a means to probe areas of chemical space that have been previously underexploited for drug or probe discovery 1 . However, to-date, there has been no critical proof of this concept with regards to new drug discovery for treatment of human disease.
Our laboratory had previously demonstrated that bacterial metabolism of L-tryptophan results in the formation of indoles and indole-derived metabolites, such as indole 3-propionic acid (IPA), which are effective ligands for both mouse and human pregnane X receptors (PXR), and can regulate host small intestinal immunity via the Toll-Like Receptor 4 (TLR4) pathway 2 . The use of PXR as a therapeutic target for inflammatory bowel disease (IBD) is a compelling concept in both rodents and humans 3 . While a variety of PXR-activating xenobiotics exist, they all have significant off-target effects in vivo (e.g., drug interactions) which limits their use as clinical drugs for IBD 4 .
Using a model developed in our laboratory 2 , we have shown that the co-occupancy of indole and indole 3-propionic acid (IPA) at the human PXR ligand-binding pocket and/or domain (LBD) is feasible. There are several opportunities to improve ligand binding via alteration of the pharmacophore H-bonding and pi-pi interactions 2 . This led us to propose that endogenous metabolite mimicry could yield more potent PXR ligands (agonists) but with limited toxicity since they would be largely derived from non-toxic metabolite-like subunits 5, 6 . Further support for this concept comes from noting that basal indole levels in feces range in the low millimolar concentrations and these levels are relatively non-toxic to mammalian cells [LD50 oral in rats ~ 1 g/kg, ThermoFisher Scientific Safety Sheet data] 7 . Similarly, indole metabolites like IPA, in feces, are likely to be present in low to high micromolar concentrations. Indeed, while these concepts have been proposed 1 , there are very few, if any, clear examples of the utility of these concepts in drug or probe discovery.
The present work was aimed at providing the requisite proof that by developing mimics of microbial indoles using limited chemical analog development, one can significantly improve binding of the indole derivatives to the receptors involved in abrogating intestinal inflammation. Several indole analogs were evaluated as specific PXR agonists and their corresponding off-target liabilities were evaluated. The safety profile of the most promising candidates was assessed in mice and human intestinal organoids in culture. Finally, the action of the PXR-specific lead compounds on intestinal inflammation in mice and human organoids was evaluated.
Results

Characterization of FKK compounds as hPXR and/or AhR agonists. Based on our novel
findings that indole and IPA can synergistically activate hPXR and can produce functional effects in vivo 2 , we hypothesized that the development of a small molecule, representing the interactions of both indole an IPA, is an innovative and potentially promising strategy for generating therapeutics for targeting PXR for diseases such as IBD. To design such molecules, we used our platform technology called the hybrid structure based (HSB) method. The HSB method utilized the interactions of both IPA and indole in the ligand binding domain (LBD) of PXR and the resulting pharmacophore was screened, and the molecules ranked by their individual docking score. Two commercial molecules FKK999 and BAS00641451(BAS451) ( Supplementary Fig. 1a ), which had docking scores of 65.89 and 52.66, respectively, were chosen as the starting point for further optimization. Docking studies demonstrated that although both FKK999 and BAS451 orient in the binding pocket of PXR to maximize their interactions with the residues from LBD, FKK999 had a better interaction profile that resembled the interactions of indole and IPA in the same site ( Supplementary Fig. 1b ). Docking of BAS451 shows several shared interactions with those of FKK999, but does not include the key ring stacking interaction with Trp299 and electrostatic interactions that contribute to the binding efficacy since BAS451 has only two indole rings and the additional phenyl ring does not compensate for the lost interactions. In PXR cell based transactivation screens, FKK999 activated PXR, BAS451 did not (data not shown). FKK999 was used for further design of improved bis-indole analogs , and all analogs were tested as PXR ligands using in silico approaches (including sites outside the LBD, courtesy AC and SV). As demonstrated by the interactions of FKK5 in the LBD ( Supplementary   Fig. 1c ) the ligand has arene-H interactions with Ser247 and Met250, electrostatic interactions with Met250 and Cys301 and other favorable interactions with Gln285, His407, Cys284, Met246 and Leu411.
The complete syntheses of indole metabolite mimics FKK1-FKK10 are reported in detail in the Supplementary Methods and Results. Crystal structures were obtained for lead compounds FKK5 ( Supplementary Fig. 1d ) and FKK6 ( Supplementary Fig. 1e ). The ligand efficiency metrics (LEM) 8 analysis 9 for the FKK compounds predicted -FKK5 and FKK6, as the best candidates for further studies (data not shown). The same LEM analysis also indicated FKK4 as an efficient agonist; however, this congener could show metabolic instability with its N-protecting group possibly generating toxic aldehydes by oxidative cleavage in vivo.
All compounds synthesized were tested for their potential to activate PXR and/or AhR via luciferase assays as previously described 10, 11, 12 . All FKK compounds demonstrate a concentration-dependent effect on PXR activation (Fig. 1a ). By contrast, only FKK2 and FKK9 at 10 μM, respectively, demonstrated significant (>100 fold) AhR activation comparable with dioxin (TCDD) control ligand. To a much lesser extent, variable degrees of dose dependent AhR activation profiles were observed for FKK3,4,7,8,10 and FKK999 (Figure 1b ). FKK compounds did not activate glucocorticoid receptor (GR) ( Supplementary Fig. 2a ), vitamin D receptor (VDR) ( Supplementary Fig. 2b ), thyroid receptor (TR) ( Supplementary Fig. 2c ) and androgen receptor (AR) ( Supplementary Fig. 2d ) using cell-based luciferase assays previously described 13, 14 . Similarly, FKK5 or 6 did not induce constitutive androstane receptor (CAR) activity ( Supplementary Fig. 2e ). Since RXR is an obligatory protein partner in the active PXR transcription complex, we also assessed the potential for FKK compounds to serve as ligands for RXR 15 . Employing a recently developed radio-ligand binding assay for RXR 16 , using nuclear extracts from rat liver, we only observed significant displacement of [ 3 H]-9-cis-retinoic acid by FKK1, and to a lesser extent by FKK8 ( Supplementary Fig. 2f ). Together, molecular docking, LEM analysis, PXR and AhR transactivation assays show that among the FKK compounds, FKK5 and FKK6 are the best chemical PXR specific ligand leads.
Characterization of FKK Compound(s) Gene Expression Assay Profile in Cells. PXR agonists
transcriptionally induce (> 2-fold) canonical target genes encoding drug metabolism enzymes/transporter, CYP3A4 and MDR1, in both liver (hepatocytes) 17 and intestinal cells (LS180) 18 . HepaRG cells simulate hepatocytes in that PXR ligands can also induce target genes in similar but not identical manner [19] [20] [21] . AhR agonists transcriptionally induce target genes, CYP1A1 and CYP1A2, in both hepatocytes 22 and intestinal cells (LS180) 23 . As shown in Fig. 1c (top panel), in LS180 cells, FKK5 and FKK6, respectively, did not induce CYP1A1 mRNA. In PXR-transfected LS180 cells, FKK6 (and to a lesser extent FKK5), induce CYP3A4 ( Fig. 1c middle panel) and MDR1 mRNA (Fig. 1c , bottom panel). In HepaRG cells harboring loss of PXR or AhR, target gene induction should be markedly diminished when compared to the wild type control cell line 24, 25 . TCDD, a known AhR ligand, induces CYP1A1 mRNA in HepaRG TM control 5F clone and PXR-KO cells. FKK5 and FKK6 did not induce CYP1A1 mRNA ( Fig. 1c , top panel). Rifampicin, a canonical PXR ligand, did not induce CYP3A4 mRNA in HepaRG TM PXR-KO cells as compared with HepaRG TM control 5F clone or HepaRG TM AhR-KO cells. FKK6 > FKK5, respectively, induce CYP3A4 mRNA only in HepaRG TM control 5F clone or HepaRG TM AhR-KO cells ( Fig. 1c , middle panel). By contrast, and unlike in LS180 cells, none of the compounds, including rifampicin, induced MDR1 mRNA (Fig. 1c , bottom panel). In primary human hepatocytes (plated, n = 4 independent samples), TCDD induced CYP1A1 mRNA in all hepatocytes. FKK5 and FKK6 did not induce CYP1A1 mRNA (Fig. 1c , top panel). Rifampicin and FKK6, unlike FKK5, showed >2fold induction in one of four hepatocyte samples ( Fig. 1c , middle panel). Similarly, FKK6, but not FKK5, showed MDR1 mRNA induction in one of four hepatocyte samples (Fig. 1c, bottom panel) .
In comparing the PXR target gene expression profile between cell-based models (Fig. 1c ), there is a greater induction of CYP3A4 and MDR1 mRNA in LS180 cells when compared with HepaRG cells or primary human hepatocytes.
Characterization of FKK Compound(s) Cell and tissue Cytotoxicity Potential. LS180 were used
to assess cell cytotoxicity using the MTT assay as previously described 13, 14 . The results show that the entire series of FKK compounds (up to 10 μM) do not significantly alter LS180 cell survival ( Supplementary Fig. 3a ). Since in vitro cytotoxicity studies do not reflect in vivo effects of metabolites as would be generated from FKK compounds in vivo (animals), an acute toxicity study was conducted in C57BL/6 mice. FKK6 was selected as a lead compound for assessment, given that it had the more favorable PXR-selective ligand activity in cell lines tested. A dose of 500 μM in 10% DMSO 26, 27 per day was chosen since this concentration represented the maximal solubility of FKK6 in an aqueous solution that could be safely administered to mice. The mice were gavaged for ten (10) consecutive days and necropsied on day 12 with collection of blood (serum). FKK6 does not alter serum chemistry profiles assessed ( Supplementary Fig. 3b ). FKK6 does not significantly impact tissue pathology when compared to control (vehicle) exposed mice ( Supplementary Table 3 ). Similarly, a 30-day toxicity test was conducted in mice using FKK6 at an oral dose of 200 μM in 0.8% DMSO per day. This dose was chosen to stay within the safe DMSO dose administered to mice over a 30-day period. On day 30, mice were necropsied with collection of blood (serum). FKK6 does not significantly alter serum chemistry profiles ( Supplementary Fig. 3c and d) or impact tissue pathology when compared to control (vehicle) exposed mice (Supplementary Table 4 ).
Characterization of FKK-induced PXR -DNA interactions via Chromatin Immunoprecipitation
(ChIP).
To determine if FKK5 and 6 are able to enhance occupancy of specific PXR DNA-binding elements (PXRE) in cells, we performed ChIP assays using LS174T cells transiently transfected with a PXR expressing plasmid. Extensively passaged LS174T cells endogenously express PXR but at low levels insufficient for good PXR protein pull-down and reporter experiments 28 . Thus, PXR transfection allows us to confidently isolate PXR occupancy effects in response to ligands. We verified a semi-quantitative ChIP using PXR-transfected LS174T cells exposed to FKK6 or its vehicle (DMSO). FKK6 augments PXR occupancy of the proximal CYP3A4 and MDR1 promoter (at their respective, PXR-binding elements) ( Fig. 1d ).
Characterization of FKK 5 and 6 as direct ligands of PXR in solution. PXR activation is
repressed via kinase-dependent phosphorylation (e.g., cdk2) 29 . FKK5 and FKK6 (DiscoverX scanMAX SM assay panel of 468 kinases) were tested as potential inhibitors of kinases in vitro and neither of these compounds inhibits the kinases tested ( Supplementary Fig. 4a & Table 5 ). Together, these results support a direct interaction of FKK compounds with PXR. To demonstrate this interaction, we performed a cell-free competitive hPXR TR-FRET binding assay. In this assay, FKK5 demonstrated an IC50 of 3.77 μM which was similar to that observed with FKK6 ~ 1.56 μM ( Fig. 1e ).
To obtain direct proof of interaction with hPXR LBD, we performed isothermal titration calorimetry (ITC) experiments using His-tagged hPXR LBD protein (PXR.1) in solution. ITC measures the affinity, Ka, and Gibbs energy (ΔG = -RTlnKa) and the changes in enthalpy, DH, and entropy, DS, associated with the binding of the FKK compounds (ΔG = -RTlnKa = ΔH -TΔS). Enthalpic and entropic contributions to binding affinity define the nature of the forces that drive the binding reaction 30, 31 . This information is conveyed in a thermodynamic signature 32, 33 and guides drug design and optimization 34 . In agreement with previously demonstrated work that IPA alone has weak hPXR LBD interactions as determined using cell based assays 2 , in this assay, unlike rifampicin, a canonical hPXR agonist , IPA does not induce a thermal signature with respect to its interaction with the hPXR LBD in solution ( Supplementary Fig. 4b ). FKK5 binds to a single site in LBD, albeit with better affinity than IPA (Kd = 0.30 µM) due to a more favorable enthalpy of binding (DH = -2.5 kcal/mol, -TDS = -6.4 kcal/mol) ( Fig. 1f ). Compared to FKK5, FKK6 binds with improved enthalpy (DH = --3.5 kcal/mol) but with an even larger loss in favorable entropy (-TDS = -4.1kcal/mol), which translates to a loss in binding affinity for FKK6 (Kd = 2.7 µM) ( Fig. 1f ).
In addition, we have previously shown that unlike rifampicin, indole in combination with IPA, is unable to activate the PXR mutant (C285I/C301A) 2 . Similarly, to test the effect FKK6 (10 μM) on this mutant, 293T cells were transfected with wild-type PXR.1 or mutant PXR.1 (C285I/C301A) plasmids along with its cognate luciferase reporter. The cells were exposed to DMSO, rifampicin (10 μM) or FKK6 (10 μM) and reporter activity assessed. While rifampicin significantly induces PXR reporter activity in both wild-type and mutant PXR transfected cells, FKK6 is unable to activate mutant PXR ( Fig. 2a ).
Together, these data show that FKK5 and FKK6 are bonafide agonist ligands of PXR.1 in solution and cells.
Characterization of FKK5 and FKK6 on PXR-TLR4 and NF-κB signaling in human colon cancer cells.
We have previously shown that PXR activation down-regulates TLR4 mRNA expression leading to inhibition of NF-κB signaling 2, 35, 36 . We have also shown that FKK5 and FKK6 interact directly with PXR LBD and result in its activation. Thus, to determine the effect of FKK5 and FKK6 on the PXR-TLR4-NF-κB signaling pathway, we used PXR-transfected Caco-2 cells and exposed these cells to FKK5 and 6 since undifferentiated Caco-2 cells inherently have low PXR expression (not detected) but relatively higher TLR4 expression and are excellent in vitro models for the study of enterocyte function [36] [37] [38] [39] . FKK5 and FKK6 down-regulates TLR4 (0.39-fold and 0.49-fold, respectively) but up-regulates CYP3A4 (3.7-fold and 3.29-fold, respectively) and MDR1 (5.12-fold and 6.45-fold, respectively) mRNA expression ( Fig. 2b) . Together, these studies provide a rationale for the study of FKK compounds on modulating the PXR-TLR4-NF-κB pathway.
To determine whether FKK5 and 6 also inhibit NF-κB signaling in intestinal cells, we used PXR and NF-κB reporter co-transfected as well as NF-κB reporter transfected LS180 intestinal cell line in early and late passage. In this assay, the enhanced expression of PXR protein was verified by immunoblotting across several repeat experiments ( Supplementary Fig. 4c ). FKK5 and FKK6, in a dose-dependent manner, significantly reduced TNFα-induced NF-κB reporter activity in PXR-untransfected and transfected LS180 cells (Fig. 2c ). The effects of FKK compounds on inhibition of TNFα-induced NF-κB reporter activity are significantly greater in PXR-transfected cells as compared with un-transfected LS180 cells ( Fig. 2c) . Notably, the trend for effects of FKK5 and FKK6 is similar across the passages of LS180 cell lines used ( Fig. 2c & d) . Notably, PXR-transfected LS180 cells induce PXR target genes (CYP3A4, MDR1) well above un-transfected cells, and FKK5 and FKK6 induce PXR target gene expression in the transfected LS180 cells ( Supplementary Fig. 4d ).
To reproduce these findings in a more robust model, we used LS174T cells, in which PXR protein is absent, via a CRISPR-Cas9 knockout of the human PXR locus (see methods). Since the LS174T PXR knockout cells (PXR-KO or NR1I2 KO) were pooled transfectants, the editing efficiency being ~ 83%, we see that these cells can gain some functional PXR activity with multiple passages ( Supplementary Fig. 5a ) even though the PXR protein expression remains very low to undetectable ( Supplementary Fig. 5b ). FKK 5 and FKK6 do not induce PXR target genes in PXR-KO cells ( Supplementary Fig. 5c ). In early passage PXR-KO cells, we used PXR and NF-κB reporter cotransfected as well as NF-κB reporter-transfected PXR-KO cell line. However, we were unable to see sustained PXR protein in the PXR transiently transfected PXR-KO cells (data not shown); thus, rather than perform the complementation experiment, we proceeded with establishing the effect of rifampicin and FKK6 in the TNF-exposed PXR-KO cell line transfected with the NF-κB reporter. Unlike the wildtype LS174T cells, neither rifampicin nor FKK6 repressed NF-κB reporter activity ( Fig. 2e ). Together, these data confirm that FKK5 and FKK6 are agonist ligands of PXR and that their activity in varied intestinal cells on repressing the TLR4 -TNF-a -NF-κB is directly via PXR.
Characterization of FKK5 and FKK6 in human colon cancer cells and intestinal organoids
exposed to inflammatory and infectious stimuli. To further characterize the anti-inflammatory effects of FKK5 and 6 on human intestinal cells and tissue, we first determined their effects on Caco-2 cell monolayers. These cells were well-established models to study intestinal cell differentiation and physiology, specifically under conditions of inflammatory stimuli 38 . Differentiated Caco-2 cells via long term culture have heightened PXR expression 40 . In Caco-2 cells, interleukin-8 (IL8) rather than IL6 is consistently a more robust pro-inflammatory cytokine (data not shown). In these cells, TNF-a significantly induced IL8 mRNA; however, only FKK6 (25 μM) significantly reduced cytokine-induced IL8 ( Fig. 3a ). Interestingly, cytokines (when compared to untreated cells) also significantly increased salmonella invasion in Caco-2 cells (Fig. 3b ). FKK5 and 6, at all concentrations tested (10 and 25 μM), when compared to cytokines only, significantly decreased cytokine-induced salmonella invasion ( Fig. 3b ). There is no significant effect of FKK5 or 6 alone on salmonella invasion ( Fig. 3b ). Similarly, in Caco-2 cells, NF-κB is a seminal regulator of both IL8 and other pro-inflammatory cytokines. In Caco-2 cells, at 2 or 12 h, cytokines (CK only) translocate most of the NF-κB signal by immunofluorescence from the cytoplasm to the nucleus (when compared to No CK) ( Fig. 3c ). In the presence of FKK5 or 6 (25 μM, respectively), however, there is increased cytoplasmic NF-κB signal, suggesting more retention of NF-κB outside the nucleus (Fig. 3c ).
While Caco-2 cultures are important models to study intestinal barrier function, they have limitations in that culture conditions can widely change the experimental results 39 . Thus, for a more accurate representation of the effects of compounds on PXR activity, especially with regards to inflammation, we investigated the effects of our FKK analogs on primary human intestinal organoids (HIOs). First, we confirmed that our analogs, FKK5 and 6, significantly induce PXR target genes ( Supplementary   Fig. 6a ). Interestingly, CYP3A4, a target gene that is only modestly (as opposed to MDR1) elevated in our intestinal cell lines exposed to FKK5 ( Fig. 1c ), was also only modestly increased in the HIO experiments (Supplemental Fig. 6a : borderline significance for CYP3A4 p = 0.056). Since HIOs can be used to study effects of FKK compounds on PXR target genes, to determine if this would correlate with their ability to inhibit TNFα mediated induction of pro-inflammatory cytokine (IL8), HIOs from different individuals were exposed to TNFα in the presence or absence of FKK5 (n = 9) or FKK6 (n = 3) or FKK9 (n = 5). In pair-wise comparison of HIOs from the same individual exposed to DMSO or FKK compounds, respectively, FKK5 (10 μM) significantly lowered IL8 mRNA levels ( Figure 4a ); similarly, FKK6 (10 μM) reduced IL8 mRNA levels in organoids but did not reach statistical significance (p = 0.07) ( Figure 4b ). FKK9, which is a strong AhR agonist but also has PXR agonist activity, did not show significant effects on IL-8 mRNA levels in this assay (Figure 4c ).
Complementing this data, in iPSC derived HIOs, cytokines induce a significant increase in IL8 mRNA levels at 12 h ( Figure 3d ; p < 0.05 Two Way ANOVA) but not at 2 h after exposure. FKK5 and FKK6 (each at 10 and 25μM, respectively), has no significant effect on basal IL8 expression ( Figure 3d ); however, when compared to cytokines alone, in the presence of cytokines both FKK5 and 6 significantly reduced IL8 mRNA expression after 12 h of exposure ( Figure 3d ). Similarly, cytokines significantly increased salmonella invasion in HIOs (Figure 3e ). FKK5 and FKK6 (both at 10 and 25 μM, respectively), had no significant effect on basal levels of salmonella invasion ( Figure 3e ); however, when compared with cytokines alone, FKK5 and FKK6, both significantly reduced salmonella invasion ( Fig. 3e ). Interestingly, salmonella invasion is significantly reduced at all timepoints studied (2, 4, 6 and 12 h post exposure to cytokines). In HIOs, at 2 or 12 h, by visual inspection of the immunofluorescence images, cytokines (CK only) translocated most of the NF-κB signal from the cytoplasm to the nucleus (CK+FKK compared to No CK) ( Fig. 3f ). In the presence of FKK 5 or 6 (25 μM, respectively), however, there was increased cytoplasmic NF-κB signal, suggesting more retention of NF-κB outside the nucleus (Fig. 3f ).
Together, these data in Caco-2 cells, HIOs derived from multiple sources and centers, suggest that PXR target gene expression in mice. The FKK compounds presented here are first generation indole/IPA analogs that have not been optimized for pharmaceutical discovery. However, to determine the effects in vivo, specifically as it relates to the ability to induce PXR target genes in different mice tissues after oral gavage, we performed studies using FKK6, our representative best lead, in C57BL/6 mice. FKK6 was gavaged at concentration ~ 500 μM in 10% DMSO and administered to C57BL/6 mice over 36 or 60 h (3 or 5 doses, respectively). There was no significant effect (< 2-fold induction with large variability) in PXR target gene (cyp3a11, mdr1a, mdr1b or mdr1) expression across organs (liver, small and large intestine) in mice ( Supplementary Fig. 6b ). In pxr -/mice exposed to FKK6, the expression levels for all target genes (cyp3a11, mdr1) are ≤ 1.5fold to that of DMSO exposed mice. Indeed, there is no biologically significant effect on PXR target gene (mdr1) expression across organs (liver, small and large intestine) in pxr -/mice ( Fig. 4e: 36 h; Supplementary Fig. 6c : 60 h). However, cyp3a11 is significantly suppressed in the small (0.25x DMSO) and large intestines (0.36x DMSO) in the 60 h exposure study ( Supplementary Fig. 6c ). These data suggest that PXR might be important in these organs as basal regulators of these genes. By contrast, there is a biologically significant induction of cyp3a11 (but not mdr1) expression in small and large intestines as compared to DMSO and/or liver cyp3a11 expression in hPXR mice when exposed to 36 h of FKK6 (three doses) ( Fig. 4f ).
Interestingly, when the FKK6 dosing is prolonged (five doses or 60 h exposure), there is a distinct increase in mdr1 expression in the liver (as compared to the intestines) and no significant effects on cyp3a11 expression in hPXR mice ( Supplementary Fig. 6d ). Together, these results demonstrate that FKK compounds induce PXR target genes in a PXR-dependent manner in mice.
Effect of FKK6 in mouse model of acute colitis in vitro and in vivo.
To characterize the effects of lead compound, FKK6, on murine colitis, adult C57Bl/6 female hPXR mice were exposed to DSS acutely. Mice either received once daily vehicle gavage plus intrarectal bolus or FKK6 (200 μM) oral gavage plus intrarectal bolus (200 μM) for 10 days until necropsy. FKK6 treated mice showed significantly less weight loss and significantly greater colon length on day 10 (Figure 5a , b). The inflammation score was significantly less for FKK6 treated mice ( Figure 5c ); however, the fecal lipocalin 2 and FITC-dextran measurements show a decreased trend only (Figure 5d , e). These findings are replicated when we use the clustering method (weight loss, colon length), wherein it correctly identifies the two groups of mice that received two different treatments. By including, fecal lipocalin 2 as a cluster feature in the analysis then the clustering method identifies the two groups of mice correctly except for one of the samples. By contrast, FKK6 did not alter weight loss, colon length, inflammation score, lipocalin 2 or FITC-dextran levels in pxr -/mice (Figure 6f -j). Together, these results show that a representative FKK lead compound, FKK6, significantly reduces dextran sodium sulfate (DSS) induced colitis in mice in a PXR-dependent manner.
Discussion
A longstanding problem in drug design and discovery is the very limited regions of chemical space that are exploited by the molecules conventionally available to small and large pharmaceuticals and academia. While it has been proposed that natural metabolite derivatives are likely to serve as more potent and well tolerated drugs, proof of this concept is lacking 1 . Herein, we show that indole compounds of the FKK series mimic the docking of the natural indole and indole propionic acid derivatives for PXR, and have produced two potent lead compounds, FKK5 and FKK6. While not optimized for therapeutic delivery, these leads showed significant activity in suppressing intestinal inflammation in vitro and, for FKK6, in mice and human tissues simulating colitis.
There are several caveats to bear in mind when evaluating the data presented. While we show direct binding of FKK6 to PXR protein, our studies have not resolved the direct binding residues that interact with FKK6. Ongoing research to obtain a crystal structure of co-crystallized PXR and FKK is currently underway. The in vivo disposition of FKK compounds and their metabolites is currently unknown. The importance of pharmacokinetic profiling is that it will allow us to partially explain the serendipitous results that our FKK compounds lack PXR activation properties in liver cells (primary hepatocytes and HepaRG), as compared with intestinal cells (LS180, LS174T). The metabolites generated in mice may also have importance, in that they could inhibit parent compound interactions with PXR, and these will be studied further. Recent research reveals that intestinal PXR activators can induce hypertriglyceridemia and metabolic perturbations 41 . We did not observe any significant changes in lipid profiles in mice exposed to either a 10-day or 30-day gavage of FKK6. Indeed, it is likely that one explanation for this might be that PXR activation can have opposing effects on lipid metabolism depending on the nature of the xenobiotic itself (i.e. non-receptor mediated action of the compound itself like anti-oxidant function) 42 . These effects may cancel out on certain pathways like lipid metabolism 42 . FKK6 has been studied with respect to a limited number of cellular targets that relate to PXR. While we find that FKK effects in cells and human intestinal organoids (HIOs) correlates with changes in PXR target gene and NF-κB signaling, it is possible that some of its protective effects could come via other targets hitherto uncharacterized (e.g., tubulin) 43 . Loss of PXR studies in HIOs would be required to confirm these correlations; these studies are in progress using both LS174T cells and iPSC cells in which PXR is knocked out using CRISPR-Cas9. We have shown that FKK6 has utility in the DSS-induced model of colitis. The use of mouse models beyond DSS induced colitis (e.g., IL10 -/-) could broaden the translatability of these compounds during preclinical drug development. Future strategies to improve solubility and targeted delivery could include formulations used in existing compounds for colon targeted delivery 44 . Despite these caveats, our studies provide and validate the initial proof-of-concept of the utility of microbial metabolite mimicry as a potential drug discovery modality.
In summary, the FKK lead compounds are suitable starting points for further optimization of potency and/or for improving drug-like qualities and similar properties for preclinical drug discovery. The applications would be in fields in which deficiency in intestinal permeability alters (worsens) disease manifestations (e.g., inflammatory bowel disease) 45 . Additionally, since these are relatively well tolerated agents, applications in chemoprevention are also possible. Our work describes the first fully realized drug discovery using microbial metabolite mimicry. These strategies could be expanded widely to other receptors (and diseases) that derive ligands from the host microbiome.
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Biology. Rifampicin, 2,3,7,8 -tetrachlorodibenzo-p-dioxin (TCDD), dexamethasone, 1α,25
Dihydroxyvitamin D3, Triiodo-L-Thyronine (T3), Dihydrotestosterone (DHT), SR12813 (S4194) were purchased from Sigma. LS174T cells were originally purchased from ATCC and prior to use cell line authenticity and was validated as previously described 46 . Caco-2 cells were purchased from ATCC and was validated by multiplexed STR DNA profiling performed by Genetica. Human Caucasian colon adenocarcinoma cells LS180 (ECACC No. 87021202) were purchased from European Collection of Cell Cultures (ECACC). Stably transfected gene reporter cell lines AZ-AHR, AZ-GR, IZ-VDRE, PZ-TR and AIZ-AR were as described elsewhere [12] [13] [14] 47, 48 . Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) or RPMI-1640 medium (cultivation of AIZ-AR cells) supplemented with 10% of fetal bovine serum, 100 U/mL streptomycin, 100 mg/mL penicillin, 4 mM L-glutamine, 1% non-essential amino acids, and 1 mM sodium pyruvate. Cells were maintained at 37 °C and 5% CO2 in a humidified incubator. HepaRG TM is a human hepatoma cell line isolated from a liver tumor of a female patient suffering from hepatocarcinoma and hepatitis C infection 49 . The cells possess a pseudodiploid karyotype and have been characterized as an oval duct bi-potent hepatic cell line as they have the ability to differentiate into both biliary and hepatocyte lineages in the presence of DMSO 50 . Three HepaRG TM derived cell lines, including 5F Clone control cells, and cells with targeted functional PXR and AhR gene knockouts, PXR-KO and AhR-KO respectively, were purchased from Sigma (CZ). Cells were handled according to the manufacturer´s protocol. Human Hepatocytes were purchased from Biopredic International (France) and Triangle Research Labs, LLC-Lonza (US).
Cultures were maintained in serum-free medium at 37 °C and 5% CO2 in a humidified incubator. and target gene induction activity through serial passages ( Supplementary Fig. 5a & b) .
Generation of PXR knockout
Cell Culture and Transfection Assays. Cells were seeded in 96 well plates, stabilized for 24 h, and then incubated for 24 h with tested compounds; vehicle was DMSO (0.1 % v/v). Incubations were performed in four technical replicates. LS180 cells transiently transfected by lipofection (FuGENE HD Transfection Reagent) with pSG5-PXR plasmid along with a luciferase reporter plasmid p3A4-luc 10,11 , were used for assessment of PXR transcriptional activity. Transcriptional activity of AHR, GR, VDR, TR and AR were studied in stably transfected gene reporter cell lines AZ-AHR, AZ-GR, IZ-VDRE, PZ-TR and AIZ-AR, respectively [12] [13] [14] 47, 48 . Cells were seeded in 96-well plates, stabilized for 24 h, and Differences were tested using one-way ANOVA with Dunnett's post hoc test, p < 0.05, was considered significant (*). For data presented in Supplementary Figure 8 , transfections and analysis of AhR activation was performed as previously published 51 . For all the transfection experiments, specifically mutiplexed transfections, the control wells were mock transfected (PXR vector). However, to exclude that PXR ligand (FKK) effect is not due to the non-specific binding of PXR (or other factors) upstream of the luciferase gene within non-PXR binding elements, we performed pilot experiments in different cell passages (P11, P14, P17) of LS174T cells using a mock luciferase plasmid (luciferase not containing an upstream PXR binding element of the CYP3A4 promoter). The PXR ligands tested were rifampicin (10 µM) and FKK6 (1-25 µM). There was no effect of these ligands at any concentration on luciferase reporter activity (data not shown).
Reverse transfection assays were performed in Caco-2 cells as previously published with the following modifications 52 . The assays were performed in a 48-well plate format using 3.0 x 10 4 cells per well using pSG5-PXR plasmid (300 ng/well); β-Gal expression plasmid (600 ng/well); CYP3A4luciferase reporter (500 ng/well) as previously published 10 . Transfection using lipofectamine ® LTX (1 μl/mg of plasmid) proceeded for 24 h followed by an additional 24 h exposure to FKK5. Cell lysates were prepared for β-Gal and luciferase assays as previously published 10 . The data are expressed as mean ± SD RLU (relative light units from luciferase assay) normalized to β-Gal activity in the same well. Differences were tested using 2-way ANOVA with Tukey's multiple comparison test, p < 0.05 was considered significant (*). Standard transient transfection assays (PXR, CAR) in HEK293T cells were performed as previously published 53 .
NF-κB reporter assays were performed using LS180 cells. Briefly, LS180 cells (Passage 8 and 13
were used since NF-κB activity can be influenced by cell passage) 54 GAPDH CTCTGCTCCTCCTGTTCGAC ACGACCAAATCCGTTGACTC 60
The following protocol was used: an activation step at 95 °C for 10 min was followed by 45 cycles of PCR (denaturation at 95 °C for 10 s; annealing with elongation at 60 °C for 30 s). The measurements were performed in triplicate. Gene expression was normalized per GAPDH as a housekeeping gene.
The data were processed according to the comparative CT method 55 Chromatin Immunoprecipitation (ChIP) Assays. LS174T cells were plated in 150-mm cell culture dishes followed by transfection with pSG5-PXR (2 μg/plate/1 x 10 7 cells). After 12 h, cells were exposed to vehicle (DMSO 0.1% v/v) or 10 μM FKK5, FKK6 or FKK9, respectively, for 24 h.
Chromatin Immunoprecipitation (ChIP) was performed using previously published protocols 46, 57 .
Briefly, cells were chemically cross-linked with formaldehyde in culture media for 15 min at room temperature. Glycine was added to a final concentration of 0.125 M to stop cross-linking for 5 min at room temperature. Cells were rinsed twice with cold PBS (pH 7.5) and scraped in PBS supplemented with protease inhibitor cocktail (PIC).
Cell pellets were collected and immediately resuspended in immunoprecipitation (IP) buffer (150 mM NaCl, 50 mM Tris-HCl at pH 7.5, 5 mM EDTA, 0.5% NP-40, 1% Triton X-100). The nuclei were centrifuged at 12000 x g for 1 min and resuspended in fresh IP buffer. Chromatin was sheared by and transferred from the unit to the lab.
Isolation of crypts and culture of human enteroids from patient-derived duodenum (and RT-
PCR assays). Discarded duodenum tissue after surgery was obtained and used to isolate crypts.
Embedded crypts in Matrigel formed three-dimentional (3D) structure referred to as 'enteroids'. The isolation protocol has been described as previously 61 . Enteroids were incubated with 10 µM compounds (FKK5, FKK6, and Rifampicin) at day 4 from isolation. DMSO was added to enteroids as negative control. After incubation for 24 h, enteroids were collected in RNA-free tube followed by breaking down Matrigel by pipetting vigorously (using 1 mL PBS). The enteroids were pelleted at Samples were immediately processed to yield isolated colonic crypts as previously described 62 . were kept in a humidified 37 °C incubator with 5% CO2. Media was changed every 2-3 days and with regular passage 1-2 times a week. For all experiments, Caco-2 cells (5 x 10 4 cells/mL) were seeded into 12 well Transwell inserts or coverslips and cultured for 3 weeks. HIOs were generated from iPSCs as described previously 63 , with some modifications. The iPSC cell line IISH1i-BM1 (WiCell., Madison, WI) was cultured on Matrigel plates to 80% confluence in mTeSR™1 medium (Stem Cell Technologies., Seattle, WA) and differentiated to endoderm using Definitive Endoderm Kit (Stem Cell Technologies., Seattle, WA) for 4 days with daily media changes. Endoderm was then differentiated to hindgut for 5 days with the addition of FGF-4 (500 ng/mL; Peprotech., Rocky Hill, NJ) and Chir99021 (3 µM; Cayman., Ann Arbor, MI) in RPMI media supplemented with 2% FBS. Floating hindgut spheroids were collected on days 3-5 of hindgut differentiation and suspended in Matrigel beads for HIO differentiation. HIOs were maintained in WENRAS media 64 HIOs and Caco-2 were exposed to a pro-inflammatory cytokine cocktail (10 ng/mL IFNγ, 10 ng/mL TNFα, 50 ng/mL IL-1β) for varying time points All mice were starved overnight (12 h) to allow for smooth intrarectal delivery; however, the mice were allowed to feed ad libitum during the day. This protocol was continued for 10 consecutive days after which mice were sacrificed and organs/tissues/feces harvested for further study. On day 10, prior to necropsy, mice were administered FITC-dextran and mouse serum was collected for the FITCdextran assay as previously described 71 . The experimenter was not blinded to treatment allocation; however, the pathologist (KS) evaluating histologic scores is blinded to treatment allocation. All TCDD  FKK5  FKK6  TCDD  FKK5  FKK6  TCDD  FKK5  FKK6  TCDD  FKK5  FKK6  TCDD  FKK5  FKK6  TCDD  FKK5  FKK6  TCDD  FKK5  FKK6  TCDD  FKK5  FKK6  TCDD  FKK5 FKK5  FKK6  RIF  FKK5  FKK6  RIF  FKK5  FKK6  RIF  FKK5  FKK6  RIF  FKK5  FKK6  RIF  FKK5  FKK6  RIF  FKK5  FKK6  RIF  FKK5  FKK6  RIF  FKK5  FKK6  0   10 In Caco-2 monolayer cells a, Log10 relative expression of IL8 mRNA with or without cytokines (50 ng/ml IL-1, 10 ng/ml IFNγ, 10 ng/ml TNF α), and cytokine cocktail plus FKK drugs (10 and 25 μM) with 2 h or 12 h incubations. b, Salmonella invasion in colony forming units per ml (CFU/ml) at the different time periods of incubation. c, confocal images of NFĸB (red) and the nucleus (blue). In human intestinal organoids (HIO), d-f are identical to a-b. The histogram, mean with 95% CI, depicts combined data from biological replicates (n = 3) with three consecutive passages of cells. Each biological replicate has three technical replicates. Results were expressed as. * p < 0.05 , two-way ANOVA with Tukey post hoc test. Confocal images shown are representative images from (n = 3) biological replicates. Fig. 4 : FKK6 inhibits cytokine mediated IL8 induction in human colonic organoids and induces PXR target genes in mice. Quantitative gene expression by RT-qPCR of IL8 mRNA from human colonic enteroids (over 40 enteroids per individual sample per well) exposed to control (vehicle) or TNF α. with or without a, FKK5. b, FKK6. c, FKK9. Data shown as mean fold change relative to vehicle control (con) for each paired sample (n = 3 replicates). Each paired sample data set represents biopsies from an individual patient. *, ## p < 0.05, Pair-wise one way ANOVA with Tukey's post hoc test. Fold induction (mRNA) of genes in d, C57BL/6 mice, e, pxr -/mice, and f, hPXR mice gavaged with vehicle (10% DMSO; n = 3) or FKK6 (500 μM in 10% DMSO; n = 3) every 12h for 3 total doses. The entire experiment was repeated two independent times and one representative experiment is shown. Each mouse (each organ) was studied in quadruplicate assays and normalized to internal control, GAPDH. The histograms show mean (95% CI) values for gene expression. * p < 0.05, two-way ANOVA with Tukey's post hoc test. After coin-toss randomization, hPXR mice were allocated to treatment with vehicle (0.8% DMSO) ( n = 3/genotype) or FKK6 (200 micromolar) (n = 3/genotype), by simultaneous oral gavage and intra-rectal delivery starting day 1 -10 of DSS administration. a, % weight loss from baseline (day 1 vs day 10) b, colon length (cm) c, Inflammation score (see methods) d, Fecal lipocalin 2 (pg/ml) e, serum FITC-dextran (µg/ml). a -c, mean (95 %CI). d,e, median (interquartile range). The entire experiment was repeated two independent times and one representative experiment is shown. *(a, b, c) p < 0.05, Welch's t-test ; *( d, e) p < 0.05, Mann-Whitney test; ns, not significant. 
